Theravance Biopharma TBPH
NASDAQ TBPH
$17.03 +0.00 (+0.00%)
At close: Sep 25, 2026 · 4:00 PM EDT

Theravance Biopharma (TBPH) Gains from Sales and Divestitures (2022 - 2024)

Updated

Theravance Biopharma's Gains from Sales and Divestitures was -$35,000 in FY2025, compared with -$34,000 in FY2024.

Analysis

Theravance Biopharma (TBPH) Gains from Sales and Divestitures (2022 - 2024) Analysis & Trends

From FY2018 onward, Theravance Biopharma has reported Gains from Sales and Divestitures for 6 years.

  • Annual Gains from Sales and Divestitures has moved between -$1.35 million (FY2023) and $2.71 million (FY2022) over five years.
  • Per Business Quant data, Gains from Sales and Divestitures in earlier years was -$34,000 in FY2024, -$1.35 million in FY2023, $2.71 million in FY2022 and -$39,000 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Theravance Biopharma 883.70 Mn -543.66 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 -163,000.00
Sep 30, 2024 163,000.00
Dec 31, 2023 1,000.00
Sep 30, 2023 -1,000.00
Jun 30, 2023 -1.32 Mn
Mar 31, 2023 -29,000.00
Sep 30, 2022 -12,000.00
Jun 30, 2022 2.50 Mn
Mar 31, 2022 218,000.00
API Access

Theravance Biopharma Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=TBPH&period=max&api_key=YOUR_API_KEY